22ND - 24TH MARCH 2017 | CANNES, FRANCE





COST OF TREATMENT ANALYSIS OF BIOSIMILAR AND INNOVATOR INFLIXIMAB IN A TERTIARY LEVEL HOSPITAL

Mondelo García C, Fernández Bargiela N, García Queiruga M, Feal Cortizas B, Lestón Vázquez M, Giménez Arufe V, Martín Herranz I

Servicio de Farmacia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 84. 15006 A Coruña, Spain.

Background

The availability of biosimilar infliximab (IFX) has been postulated to offer cost savings compared to innovator IFX, which could lead to patients being switched between products.

*To analyze the demographic characteristics and pathologies of patients treated with infliximab and to evaluate the cost effectiveness of switching from innovator to biosimilar drug.

Material and methods

Observational retrospective six-month study. Sample: 100% patients treated with IFX. Data sources: electronic medical records (IANUS®), pharmaceutical application (SIMON®), management application (SINFHOS®) and pharmaceutical records.

Analyzed data number of intravenous mixtures prepared, number of patients, age, sex, weight, diagnosis, treatment received, dosage and cost of the treatment


Results



616 prepared intravenous mixtures

70.5% innovatorIFX 29.5% biosimilarIFX





Diagnosis	Number of patients
Crohn disease	31
Ulcerative colitis	27
Psoriatic arthritis	25
Rheumatoid arthritis	23
Ankylosing spondylitis	18
Psoriasis	2
Others	5

Doses	Number of patients
5 mg/kg	81
3 mg/kg	50

58 patients with biosimilar IFX 26 men (44.8%) 32 women (55.2%) 42.5 years-old (8-72) Average age 65.8 Kg (23-160 Kg) Average weight

Diagnosis	Number of patients
Ulcerative colitis	14
Crohn disease	11
Psoriatic arthritis	11
Rheumatoid arthritis	7
Ankylosing spondylitis	6
Psoriasis	1
Others	8

Doses	Number of patients
5 mg/kg	36
3 mg/kg	22

Drug	Expenditure (€)
Innovative drug	508,297.20
Biosimilar drug	177,923.20

Total expenditure 686,505.40 €

If all patients were treated with the biosimilar drug

Estimated annual saving 144,024 €

Conclusions

- ❖ Biosimilar drugs are a good alternative compared with innovator drugs due to the saving which can be obtained with their use.
- Doing a close follow-up of the patients treated with biosimilar IFX would be very important to evaluate long. term efficacy and safety of the treatment.